117 results match your criteria: "Paris-Est Créteil University (UPEC)[Affiliation]"
World J Pediatr
January 2025
EPI-PHARE, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), 143-147 Boulevard Anatole France, 93285, Saint-Denis, France.
Background: Data on biosimilar use in pediatric inflammatory bowel diseases (IBD) are scarce compared to the status of studies in adults, resulting in limitations in its treatment. We compared effectiveness and safety of biosimilars versus originators in this population.
Methods: We used data from the French National Health Data System to identify children (less than 18 years old at treatment initiation) initiating treatment with a biosimilar or the originator infliximab or adalimumab for Crohn's disease (CD) or ulcerative colitis (UC), from first biosimilar launch (January 2015 and October 2018, respectively) to 31 December 2022.
The TOPASE study was set up to evaluate the outcomes of chronic myeloid leukaemia [CML] patients treated with ponatinib (PON) in a real-world setting in France. One hundred and twenty CML patients, 105 in chronic phase (CP), 8 in accelerated phase (AP) and 7 in blastic phase (BP) were included. Fifty-one (49%) of the CP-CML patients were in third line of treatment.
View Article and Find Full Text PDFEur J Neurol
January 2025
EPI-PHARE Scientific Interest Group (French National Agency for the Safety of Medicines and Health Products, and French National Health Insurance), Saint-Denis, France.
Background And Purpose: Chlormadinone acetate (CMA) is a synthetic progestin for which cases of intracranial meningioma have been reported following prolonged exposure.
Method: An observational cohort study was conducted based on the French national health data system. Women aged 10-70 years and who started CMA between 2007 and 2017 were included.
J Am Soc Nephrol
October 2024
Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.
Brain Behav Immun
January 2025
INSERM U955 IMRB, Translational Neuropsychiatry laboratory, AP-HP, Hôpital Henri Mondor, DMU IMPACT, Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Paris Est Créteil University (UPEC), Fondation FondaMental, ECNP Immuno-NeuroPsychiatry Network, 94010 Créteil, France. Electronic address:
In last few decades, considerable evidence has emphasized the significant involvement of mitochondria, often referred to as the "powerhouse of the cell," in the pathophysiology of bipolar disorder (BD). Given crucial mitochondrial functions in cellular metabolism and inflammation, both of which are compromised in BD, this perspective review examines the central role of mitochondria in inflammation and metabolism within the context of this disorder. We first describe the significance of mitochondria in metabolism before presenting the dysregulated inflammatory and metabolic processes.
View Article and Find Full Text PDFFront Bioeng Biotechnol
September 2024
Institut Pasteur, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche (UMR) 1222, Antibodies in Therapy and Pathology, Paris, France.
Droplet-based microfluidics techniques coupled to microscopy allow for the characterization of cells at the single-cell scale. However, such techniques generate substantial amounts of data and microscopy images that must be analyzed. Droplets on these images usually need to be classified depending on the number of cells they contain.
View Article and Find Full Text PDFInflamm Bowel Dis
September 2024
Medizinische Universität Wien Klinische Abt. Gastroenterologie & Hepatologie, AKH Wien Arbeitsgruppe Chronisch Entzündliche Darmerkrankungen (CED) Währinger Gürtel 18-20, Wien, Austria.
Eur Neuropsychopharmacol
December 2024
Paris Est Créteil University (UPEC), AP-HP, University Hospital Henri Mondor (Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), INSERM U955 IMRB, Translational Neuropsychiatry laboratory, Fondation FondaMental ECNP Immuno-NeuroPsychiatry Network, France. Electronic address:
J Affect Disord
November 2024
Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Mitochondrial Innovation Initiative, MITO2i, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic address:
Background: Nutrition is largely affected in bipolar disorder (BD), however, there is a lack of understanding on the relationship between dietary categories, BD, and the prevalence of metabolic syndrome. The objective of this study is to examine dietary trends in BD and it is hypothesized that diets with increased consumption of seafood and high-fiber carbohydrates will be correlated to improved patient outcomes, and a lower frequency of metabolic syndrome.
Methods: This retrospective cohort study includes two French cohorts.
Psychiatry Res
September 2024
Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Mitochondrial Innovation Initiative, MITO2i, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Microbiol Spectr
August 2024
Université Paris Cité, Faculté de Médecine, APHP, Hôpital Necker Enfants-Malades, Hôpital Européen Georges Pompidou, Unité de Parasitologie-Mycologie, Service de Microbiologie, Paris, France.
Unlabelled: Mucormycosis is a severe and emerging invasive fungal infection associated with high mortality rates. Early diagnosis is crucial for initiating specific antifungal treatment, with molecular tools currently representing the most efficient diagnostic approach. Presently, a standardized in-house real-time PCR method is widely employed for diagnosing mucormycosis.
View Article and Find Full Text PDFLancet Reg Health Eur
July 2024
EPI-PHARE Scientific Interest Group (French National Agency for the Safety of Medicines and Health Products, and French National Health Insurance), Saint-Denis, France.
Background: Nomegestrol acetate (NOMAC) is a synthetic potent progestogen. This study aimed to assess the risk of intracranial meningioma associated with the prolonged use of NOMAC.
Methods: Observational cohort study using SNDS data (France).
J Fungi (Basel)
May 2024
Faculty of Medicine, Paris Cité University, Necker Campus, 75015 Paris, France.
Invasive fungal infections have recently been recognized by the WHO as a major health, epidemiological, and economic issue. Their high mortality rates and the emergence of drug resistance have driven the development of new molecules, including olorofim, an antifungal belonging to a new family of compounds, the orotomides. A review was conducted on the PubMed database and the ClinicalTrials.
View Article and Find Full Text PDFClin Gastroenterol Hepatol
December 2024
Department of Gastroenterology, INFINY Institute, FHU-CURE, INSERM NGERE, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
Background & Aims: The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with Crohn's Disease (CD).
Methods: From May 2021 to August 2023, all consecutive patients with CD treated with risankizumab in 25 GETAID centers have been retrospectively included. The primary endpoint was steroid-free clinical remission (Harvey Bradshaw Index [HBI] <5) at 52 weeks.
Sci Immunol
April 2024
Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct cohorts of patients with UC. A decrease in naïve B and T cells in the intestines and gut-homing (β7) plasmablasts in circulation of VDZ-treated patients suggested that VDZ targets gut-associated lymphoid tissue (GALT).
View Article and Find Full Text PDFEClinicalMedicine
April 2024
Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Paris (AP-HP), Clinical Investigation Center (CIC-1901), Regional Pharmacovigilance Centre, Department of Pharmacology, Pitié-Salpêtrière Hospital, Paris, France.
BMJ
March 2024
EPI-PHARE Scientific Interest Group, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France.
Objective: To assess the risk of intracranial meningioma associated with the use of selected progestogens.
Design: National case-control study.
Setting: French National Health Data System (ie, ).
Transpl Int
March 2024
AP-HP, Service de Néphrologie et de Transplantation Rénale, Fédération Hospitalo-Universitaire « Innovative Therapy for Immune Disorders », CHU Henri Mondor, Créteil, France.
Late opportunistic infections (OI) occurring beyond the first year after kidney transplantation (KT) are poorly described and not targeted by prophylactic strategies. We performed a ten-year retrospective monocentric cohort study describing epidemiology, risk factors and impact of late OI occurring 1 year after KT. We included clinically symptomatic OI requiring treatment besides BK virus nephropathy.
View Article and Find Full Text PDFEur J Ophthalmol
November 2024
Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Paris-Est Créteil University (UPEC, Paris XII University), Créteil, France.
Objective: To assess the effectiveness and safety of a rigorous short-term supine position in preventing inadvertent retinal displacement after pars plana vitrectomy (PPV) with gas tamponade for rhegmatogenous retinal detachment (RRD).
Methods: We conducted a retrospective observational analysis of a case series at two ophthalmological surgical centers. We included eyes diagnosed with macula-off RRD that maintained a strict face-up position for three hours immediately after PPV with intraoperative perfluorocarbon liquid (PFCL) and 20% sulfur hexafluoride (SF6) tamponade.
RMD Open
March 2024
EPI-PHARE, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), Saint-Denis, France.
J Invest Dermatol
July 2024
Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) EA7379, Paris Est Créteil University (UPEC), Créteil, France; Department of Dermatology, Hôpital Henri Mondor, Créteil, France.
J Invest Dermatol
March 2024
Dermatology Department, Henri Mondor Hospital, Assitance Publique Hôpitaux de Paris (AP-HP), Créteil, France; Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), Paris Est Créteil University (UPEC), Créteil, France; University Hospital Federation (FHU) TRUE (InnovaTive theRapy for immUne disordErs), Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France; INSERM, Clinical Investigation Centre 1430, Henri Mondor Hospital, Créteil, France.
Minerva Anestesiol
February 2024
Department of Anesthesia and Intensive Care, Cochin University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Innovation and new technologies have always impacted significantly the anesthesiology practice all along the perioperative course, as it is recognized as one of the most transformative medical specialties specifically regarding patient's safety. Beside a number of major changes in procedures, equipment, training, and organization that aggregated to establish a strong safety culture with effective practices, anesthesiology is also a stakeholder in disruptive innovation. The present review is not exhaustive and aims to provide an overview on how innovation could change and improve anesthesiology practices through some examples as telemedicine (TM), machine learning and artificial intelligence (AI).
View Article and Find Full Text PDFUnited European Gastroenterol J
October 2023
Gastroenterology Department, Paris Est Créteil University UPEC, Henri Mondor Hospital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for ImmUne DisordErs, Créteil, France.
Acute severe ulcerative colitis (ASUC) occurs in up to 25% of patients with ulcerative colitis (UC). Therapeutic approaches have evolved during the past years with the increasing bio exposure of admitted patients and the extension of the number of approved drugs for UC. In this review, we aimed to summarize the latest evidence in short-term and long-term medical strategies for ASUC.
View Article and Find Full Text PDF